Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Even as Novo Nordisk rides the momentum of Rybelsus' hot launch, the company is testing higher-dose versions of the diabetes drug that could broaden its reach in a competitive market. Now, as part of the effort, the company is declaring a late-stage win.